Analytical Data
-
Gene name
FCRLA
- Application
-
Alternative Names
FCRLA; FCRL; FCRL1; FCRLM1; FCRX; FREB; UNQ291/PRO329Fc receptor-like A; Fc receptor homolog expressed in B-cells; Fc receptor-like and mucin-like protein 1
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q7L513
-
Expression Region
28-359aa
-
AA Sequence
ASF ETLQCEGPVC TEESSCHTED DLTDAREAGF QVKAYTFSEP FHLIVSYDWL ILQGPAKPVF EGDLLVLRCQ AWQDWPLTQV TFYRDGSALG PPGPNREFSI TVVQKADSGH YHCSGIFQSP GPGIPETASV VAITVQELFP APILRAVPSA EPQAGSPMTL SCQTKLPLQR SAARLLFSFY KDGRIVQSRG LSSEFQIPTA SEDHSGSYWC EAATEDNQVW KQSPQLEIRV QGASSSAAPP TLNPAPQKSA APGTAPEEAP GPLPPPPTPS SEDPGFSSPL GMPDPHLYHQ MGLLLKHMQD VRVLLGHLLM ELRELSGHRK PGTTKATAE
-
Molecular Weight
38.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FCRLB (Fc receptor-like B) is a protein that plays a significant role in immune regulation and has garnered attention in the field of immunology and therapeutic development. Initially identified as a receptor that binds to immunoglobulins, FCRLB is believed to modulate immune responses by influencing B cell signaling and function. Research has shown that abnormal expression of FCRLB is associated with various autoimmune diseases and cancers, highlighting its potential as a biomarker and therapeutic target. Understanding the structure and function of FCRLB through recombinant protein studies is crucial for elucidating its biological roles and mechanisms. Recombinant FCRLB can be produced in various systems to study its interactions with antibodies, assess its impact on immune cell activation, and explore its therapeutic potential in modulating immune responses. Advances in recombinant technologies facilitate the production of active FCRLB proteins, enabling detailed biochemical characterization and functional assays. These studies contribute to a deeper understanding of how FCRLB influences the immune system and pave the way for innovative strategies in treating immune-related disorders. Research on FCRLB reaffirms the importance of Fc receptor biology in immune regulation and offers prospects for harnessing this knowledge in clinical applications.











